At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.
At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.
At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.
Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.
Data presented from the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials at 2021 EHA indicate success of momelotinib in extending overall survival in patients with myelofibrosis who achieve transfusion independence.
At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.
Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.
Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.
An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.
Real-world evidence evaluating the efficacy of rituximab maintenance following frontline BR or R-CHOP supports its use in mantle cell lymphoma.